TAG:
pathology specimen
Single-Specialty Path PPMs Posting Strong Growth, Profits
By Robert Michel | From the Volume VII No. 3 – February 14, 2000 Issue
CEO SUMMARY: Although the financial travails of the physician practice management (PPM) industry are widely known, there is little recognition that a number of single-specialty PPMs are doing well. This is true of pathology, where at least six pathology-based PPMs still remain in business…
Pathology Profession Facing New Directions
By Robert Michel | From the Volume VII No. 2 – January 24, 2000 Issue
CEO SUMMARY: Big changes ahead during the next decade. Among the predictions: the number of two and three-pathologist group practices will radically diminish; pathology centers of excellence will achieve new market dominance; and…ever more intense competition for anatomic pathology spec…
Abbott, CARESIDE, Bio-Reference Labs, DIANON Systems
By Robert Michel | From the Volume VII No. 1 – January 3, 2000 Issue
SWARM OF LAWSUITS NOW PLAGUES ABBOTT LABS PAYING A $100 MILLION FINE TO THE Food and Drug Administration (FDA) did not end Abbott Laboratories, Inc.’s problems related to its diagnostic test kits and reagents. Since payment of the FDA fine last month, Abbott has been serv…
PathSOURCE Is Newest Pathology Consolidator
By Robert Michel | From the Volume V No. 15 – November 9, 1998 Issue
CEO SUMMARY: Based in New York, PathSOURCE becomes the newest pathology network and services company to hit the market. PathSOURCE’s organizers want to link “best in class” dermatopathologists and academic pathology subspecialists to compete for outreach pathology specimens. PathSOU…
MedPartners To Divest Hospital-Based MD Unit
By Robert Michel | From the Volume V No. 9 – July 6, 1998 Issue
CEO SUMMARY: Hospital-based pathologists are increasingly the target of buy-out offers by the emerging group of pathology based physician practice management (PPM) companies. But MedPartners decided that managing hospital-based physicians was something that was not in its best interest. W…
Selling A Pathology Practice: Do’s, Don’ts & Pitfalls To Avoid
By Robert Michel | From the Volume V No. 5 – April 13, 1998 Issue
CEO SUMMARY: Physician practice management (PPM) companies represent a powerful new economic trend. Greater numbers of pathologists will soon confront a career-changing decision: should we sell our pathology practice to a PPM? Regardless of how pathologists answer that question, their bus…
DIANON Systems Acquires Pathology Lab In Florida
By Robert Michel | From the Volume V No. 3 – March 2, 1998 Issue
CEO SUMMARY: Another national pathology player is betting on Florida. DIANON Systems, Inc.’s purchase of a local pathology laboratory raises the competitive bar in Florida. With AmeriPath and Pathology Service Associates already gearing up to battle for market share, DIANON’s local pr…
Pathology Competitors Make Florida The Target
By Robert Michel | From the Volume V No. 3 – March 2, 1998 Issue
CEO SUMMARY: Florida is about to become the marketing battleground for anatomic pathology. Three well-funded players are preparing to launch major sales efforts. Pathologists in the state wait with trepidation. Expectations of discounted pricing and a “gloves-off” sales strategy conce…
Physician Solutions Gets Venture Capital Funding
By Robert Michel | From the Volume IV No. 17 – December 8, 1997 Issue
CEO SUMMARY: Physician Solutions becomes the second pathology-based physician practice management company to receive venture capital funding. The company is poised to acquire a number of pathology practices in cities throughout the United States. It is another sign that traditional pathol…
Success Seems Elusive To Pathology Innovators
By Robert Michel | From the Volume IV No. 6 – April 21, 1997 Issue
CEO SUMMARY: Attempts to organize pathology practice management companies encounter resistance and market impediments. Success requires an astute business plan and a sophisticated management team to convince pathologists to abandon proven practice models and affiliate with regional or nat…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized